Literature DB >> 28194716

Irradiation enhances dendritic cell potential antitumor activity by inducing tumor cell expressing TNF-α.

Lijia Chang1, Zhengzheng Zhang1, Fang Chen1, Wen Zhang1, Shuang Song1, Shuxia Song2.   

Abstract

Dendritic cells (DCs)-based tumor vaccines have shown to be the promising methods for inducing therapeutic antitumor response. However, DCs alone rarely carry curative antitumor activity, and the immunosuppressive microenvironment may contribute to this defect of DC vaccinal function. Irradiation in combination with DCs has been shown to promote immune-mediated tumor destruction in preclinical studies. However, little is known about how irradiation alters the tumor microenvironment, and what host pathways modulate the activity of administrated DCs. In this study, BALB/c mice and the 4T1 breast cancer cell line were used in a tumor-bearing model. The tumor-bearing mice were irradiated locally up to 10 Gy for 3 consecutive days or a single dose of 30 Gy using a cesium source. Studies of dynamic change of the tumor microenvironment in irradiated versus untreated tumors revealed that there was no obvious change on IL-10, IL-6 and TGF-β expression or production, whereas increased TNF-α level within the first 2 weeks of irradiation. The increased TNF-α level is exactly right timing window for DCs injection, corresponding to the significant elevation of intratumoral CD8+ T infiltration and the regression of tumor size. With attention to scheduling, combination X-ray with DCs i.t. injection may offer a practical strategy to improve treatment outcomes.

Entities:  

Keywords:  DC vaccine; Irradiation; Microenvironment; TNF-α; Tumor-bearing mice

Mesh:

Substances:

Year:  2017        PMID: 28194716     DOI: 10.1007/s12032-016-0864-3

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  36 in total

1.  Heat shock protein 70, released from heat-stressed tumor cells, initiates antitumor immunity by inducing tumor cell chemokine production and activating dendritic cells via TLR4 pathway.

Authors:  Taoyong Chen; Jun Guo; Chaofeng Han; Mingjin Yang; Xuetao Cao
Journal:  J Immunol       Date:  2009-02-01       Impact factor: 5.422

Review 2.  Antitumor immune responses induced by ionizing irradiation and further immune stimulation.

Authors:  Benjamin Frey; Yvonne Rubner; Lorenz Kulzer; Nina Werthmöller; Eva-Maria Weiss; Rainer Fietkau; Udo S Gaipl
Journal:  Cancer Immunol Immunother       Date:  2013-09-20       Impact factor: 6.968

Review 3.  Radiation-induced stress proteins - the role of heat shock proteins (HSP) in anti- tumor responses.

Authors:  T E Schmid; G Multhoff
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

Review 4.  Immune modulation by ionizing radiation and its implications for cancer immunotherapy.

Authors:  Eric J Friedman
Journal:  Curr Pharm Des       Date:  2002       Impact factor: 3.116

5.  In Situ Tumor Vaccination by Combining Local Radiation and Tumor-Specific Antibody or Immunocytokine Treatments.

Authors:  Zachary S Morris; Emily I Guy; David M Francis; Monica M Gressett; Lauryn R Werner; Lakeesha L Carmichael; Richard K Yang; Eric A Armstrong; Shyhmin Huang; Fariba Navid; Stephen D Gillies; Alan Korman; Jacquelyn A Hank; Alexander L Rakhmilevich; Paul M Harari; Paul M Sondel
Journal:  Cancer Res       Date:  2016-05-06       Impact factor: 12.701

6.  Radiation-induced IFN-gamma production within the tumor microenvironment influences antitumor immunity.

Authors:  Amit A Lugade; Elizabeth W Sorensen; Scott A Gerber; James P Moran; John G Frelinger; Edith M Lord
Journal:  J Immunol       Date:  2008-03-01       Impact factor: 5.422

7.  TLR4-dependent activation of dendritic cells by an HMGB1-derived peptide adjuvant.

Authors:  Rebecca Saenz; Diahnn Futalan; Lien Leutenez; Fien Eekhout; Jessie F Fecteau; Simeon Sundelius; Stig Sundqvist; Marie Larsson; Tomoko Hayashi; Boris Minev; Dennis Carson; Sadik Esener; Bradley Messmer; Davorka Messmer
Journal:  J Transl Med       Date:  2014-08-14       Impact factor: 5.531

8.  Inhibition of IL-17A suppresses enhanced-tumor growth in low dose pre-irradiated tumor beds.

Authors:  Eun-Jung Lee; Hyo Jin Park; Ik-Jae Lee; Won Woo Kim; Sang-Jun Ha; Yang-Gun Suh; Jinsil Seong
Journal:  PLoS One       Date:  2014-09-02       Impact factor: 3.240

9.  Dendritic Cell (DC) Vaccine in Mouse Lung Cancer Minimal Residual Model; Comparison of Monocyte-derived DC vs. Hematopoietic Stem Cell Derived-DC.

Authors:  Soyoung Baek; Seog Jae Lee; Myoung Joo Kim; Hyunah Lee
Journal:  Immune Netw       Date:  2012-12-31       Impact factor: 6.303

10.  Effects of single or combined treatments with radiation and chemotherapy on survival and danger signals expression in glioblastoma cell lines.

Authors:  Francesca Pasi; Alessandro Paolini; Rosanna Nano; Riccardo Di Liberto; Enrica Capelli
Journal:  Biomed Res Int       Date:  2014-07-01       Impact factor: 3.411

View more
  4 in total

Review 1.  Current State of Dendritic Cell-Based Immunotherapy: Opportunities for in vitro Antigen Loading of Different DC Subsets?

Authors:  Anne Huber; Floris Dammeijer; Joachim G J V Aerts; Heleen Vroman
Journal:  Front Immunol       Date:  2018-12-03       Impact factor: 7.561

2.  Monocyte Maturation Mediators Upregulate CD83, ICAM-1 and MHC Class 1 Expression on Ewing's Sarcoma, Enhancing T Cell Cytotoxicity.

Authors:  Emilie Biele; Sebastian J Schober; Carolin Prexler; Melanie Thiede; Kristina von Heyking; Hendrik Gassmann; Jennifer Eck; Busheng Xue; Stefan Burdach; Uwe Thiel
Journal:  Cells       Date:  2021-11-08       Impact factor: 6.600

Review 3.  Paving the Way to Solid Tumors: Challenges and Strategies for Adoptively Transferred Transgenic T Cells in the Tumor Microenvironment.

Authors:  Franziska Füchsl; Angela M Krackhardt
Journal:  Cancers (Basel)       Date:  2022-08-29       Impact factor: 6.575

Review 4.  Local Destruction of Tumors and Systemic Immune Effects.

Authors:  Karl-Göran Tranberg
Journal:  Front Oncol       Date:  2021-07-08       Impact factor: 6.244

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.